Latest Post

This blog discusses a patent law case which SCOTUS has decided hear on the enablement requirement as it applies to genus claims.  The anticipated decision will have ramifications in particular in the life sciences industry which includes the biotech and pharmaceutical industries.

Background

Even if the invention described in a patent application meets the subject matter eligibility (35 U.S.C §

Subscribe: Subscribe via RSS